Biographical note

Dorothy H.Bray, PhD

pharmacist, researcher

  • C-Level experience in large and small companies in North America and Europe
  • Academic track record in scientific leadership delivering novel discoveries and business strategy
  • European Commission's Scientific Expert since 1994
  • Worldwide network of collaborations with pharmaceutical companies, governments, and non- government organizations in all key markets

Dr Dorothy H Bray is ImmunoClin’s founder with sound expertise in pharmaceutical business development, pre-clinical and clinical development for novel pharmaceuticals and functional food products. She served in several key positions at GlaxoSmithKline Glaxo Wellcome Inc, USA, Glaxo Wellcome, UK and the Wellcome Foundation, UK. Dr Bray has extensive network of collaborations with pharmaceutical companies, governments, and non-government organizations in key developed and emerging markets and is is the European Commission's Scientific Expert since 2003. She acts as a business advisor to multiple biotechnology companies. In addition to her industrial activities she served as a Member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit in the UK, currently holds an honorary Senior Lecturer position at the Royal Free School of Medicine, University of London and serves as a reviewer for a number of scientific journals.

Industrial positions: 1993present

ImmunoClin Corporation: Director, President and CEO since December 2013: Brand development and leadership to formulate and implement strategic plan to establish IMMUNOCLIN CORPORATION (IMCL) as a leader in personalised medicine approach providing solutions to challenges in delivering patient focussed care. Cannabis Science, Inc.: Head of Scientific Advisory Board since November 2014 (acted as Director, President and CEOfrom May 2013May 2015): Strategic consulting, including business plan and clinical development for Company’s products, CANNABIS SCIENCE works with leading experts in drug development to develop, produce, and commercialize novel therapeutic approaches using cannabis based products with the initial focus is on the skin cancers and neurological conditions. Omnicanna Health Solutions, Inc: Board Director: May 2013present (President and CEO from May 2013May 2015): With the aid of scientific research, OMNICANNA Health Solutions is developing effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands.ImmunoClin Ltd: Director: 2002present (business owner till December 2013).

Working to development personalized medicine and nutrition platform to develop novel solutions to manage ageing society. ImmunoClin's portfolio includes prognostic markers for cardiovascular and Alzheimer's diseases, novel broad-spectrum anti-infectious therapy and innovative e-biosensor to detect bacteria, viruses and small molecules. Based upon its R&D in nutrigenomics ImmunoClin is developing novel nutritional products to combat inflammatory conditions.

GlaxoSmithKline: 1993–2002: Directed large international clinical research programme in collaboration with multiple academic and commercial organizations to develop new interventions in infectious diseases including HIV Director, Clinical Development HIV, with global responsibility, GlaxoSmithKline, UK: 1998–2002 Senior Medical Strategy Head, Glaxo Wellcome, Inc: 1997–1999 Principal Clinical Research Scientist, Antivirals, Glaxo Wellcome, UK and USA: 1995–1997 Senior Clinical Research Scientist, The Wellcome Foundation, UK: 1993–1995.

Academic Research: 1979present

Honorary Senior Lecturer, Royal Free and University College Medical School: 2002present: Application of clinical immunology in development of pharmaceutical interventions in the area of infectious diseases Head, Scientific Business Development, The Medical Research Council Clinical Trials Unit: 2004–2011 Research Fellow, Clinical Immunology, Royal Free Hospital Medical School, UK: 1990–1993, Research on the role of immune system in lung pathology Royal Society Visiting Scientist, Universite de Paris-Sud, Biochimie-Biophysique, France: 1989–1990 Research Fellow, Med. Parasitology, London School of Hygiene and Tropical Medicine, UK: 1983–1989 Research Fellow, School of Pharmacy, University of London, UK: 1982–1983 Research Assistant, ARC Institute of Animal Physiology, Babraham, Cambridge, UK: 1981–1982 Research Fellow, Polish Academy of Sciences Institute of Pharmacology, Cracow, Poland: 1979–1981.

Awards/Scholarships:

  • EEC training in Neurobiology, Strasbourg, France
  • PhD scholarship from The School of Pharmacy, University of London
  • Winston Churchill Travelling Fellowship to study medicinal plants in Africa
  • Sir Halley Stewart Trust Fellowship to study natural products
  • The Royal Society scholarship to study immunology in Paris

Education:

  • PhD degree from the School of Pharmacy, University of London: 1988
  • MSc (1st Class) in Biology, The Jagiellonian University of Cracow, Poland: 1979

Lectures and workshops on our seminars

2017 Clinical studies with cannabis and cannabinoids Abstract
2017 Clinical studies with cannabis and cannabinoids Workshop
2019 Clinical studies with cannabis and cannabinoids Abstract